Gonavet Veyx 50 micrograms/ml Solution for Injection for Cattle, Pigs and Horses

País: Reino Unido

Idioma: inglés

Fuente: VMD (Veterinary Medicines Directorate)

Ingredientes activos:

Gonadorelin[6-D-Phe]

Disponible desde:

Veyx-Pharma GmbH

Código ATC:

QH01CA01

Designación común internacional (DCI):

Gonadorelin[6-D-Phe]

formulario farmacéutico:

Solution for injection

tipo de receta:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapéutico:

Cattle, Horses, Pigs

Área terapéutica:

Hormone sex

Estado de Autorización:

Authorized

Fecha de autorización:

2015-03-31

Ficha técnica

Revised May 2020
AN: 00676/2019
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Gonavet Veyx 50 micrograms/ml Solution for Injection for Cattle, Pigs
and Horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1.0 ml contains:
ACTIVE SUBSTANCE:
Gonadorelin[6-D-Phe]
50 micrograms (equivalent to 52.4 micrograms
Gonadorelin[6-D-Phe] acetate)
EXCIPIENTS:
Chlorocresol
1 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (cows, heifers), pigs (sows, gilts), horses (mares)
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Control and stimulation of reproduction in cattle and pigs. Treatment
of ovarian-
related fertility disorders or dysfunctions in cattle and horses.
Cattle (cows, heifers):

Ovulation induction in case of delayed ovulation due to LH-deficiency

Induction/synchronization of ovulation within the framework of systems
for timed
inseminations

Stimulation of the ovaries during the puerperal period from day 12
post partum

Ovarian cysts (due to LH-deficiency)
Pigs (sows, gilts):

Induction/synchronization of ovulation within the framework of systems
for timed
insemination and parturition synchronization
Horses (mares):

Acyclia and anoestrus due to LH-deficiency
4.3
CONTRAINDICATIONS
Do not use in cows with a mature tertiary follicle ready to ovulate.
Do not use during infectious diseases and other relevant health
disorders.
Do not use in cases of known hypersensitivity to the active substance
or to any of the
excipients.
Revised May 2020
AN: 00676/2019
Page 2 of 6
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
To maximise conception rates of cows to be treated with GnRH-PGF
2α
based
synchronization protocols, the ovarian status should be determined and
regular cyclic
ovarian activity confirmed. Optimal results will be achieved in
healthy normally cycling
cows.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in an